Global Chemotherapy Market size surpassed USD 5 billion in 2016 and is anticipated to witness over 11.50% CAGR from 2019 to 2024
Global
Chemotherapy Market: Information by Drug Class (Alkylating Agents, Mitotic
Inhibitors, Antimetabolites, Topoisomerase Inhibitors and Antitumor
Antibiotic), Indication (Lung Cancer, Breast Cancer, Colorectal Cancer,
Prostate Cancer, Stomach Cancer, Lymphoma, Leukemia and Ovarian Cancer), Route
of Drug Administration (Intravenous, Oral, Subcutaneous, Intra-Muscular,
Intravesicular, Topical, Intraperitoneal and Intraventricular/Intrathecal) and
End-User (Specialty Centers and Hospitals & Clinics) - Global Forecast till
2027
Chemotherapy Market Highlights
The Global Chemotherapy Market is
estimated to be valued at USD 56,491.59 Million by 2024 and is expected to
register a CAGR of 11.50% during the forecast period.
The alkylating agents segment
dominated the global chemotherapy market, by drug class, and is projected to
reach USD 20,360.32 Million by 2024 and projected to be the fastest-growing
segment during the forecast period.
Americas dominated the market,
accounting for the largest share of the market in 2018, and the regional market
is expected to register a CAGR of 10.88% during the review period. The European
market was the second largest in 2018. The market is projected to reach USD
18,292.73 Million by the end of 2024, with Germany being the leading market.
Segment
Analysis
The Global Chemotherapy Market
has been segmented on the basis of drug class, indication, route of
administration, end user, and region. On the basis of drug class, the market
has been divided into alkylating agents, antimetabolites, mitotic inhibitors,
antitumor antibiotic, and topoisomerase inhibitors. The alkylating agents
segment held the majority market share in 2018 and anticipated to be the
fastest growing, followed by the mitotic inhibitors segment.
On the basis of indication, the
market has been divided into lung cancer, breast cancer, colorectal cancer,
prostate cancer, stomach cancer, leukemia, lymphoma, and ovarian cancer. The
lung cancer segment accounted for the larger market share in 2018. However, the
breast cancer segment is expected to exhibit higher CAGR during the forecast
period.
On the basis of route of
administration, the market has been divided into intravenous, oral, subcutaneous,
intra-muscular, intravesicular, topical, intraperitoneal, and intraventricular/
intrathecal. The intravenous segment accounted for the larger market share in
2018. However, the oral segment is expected to exhibit higher CAGR during the
forecast period.
On the basis of end user, the
market has been divided into specialty centers, hospitals & clinics, and
others. The specialty centers segment accounted for the larger market share in
2018 and expected to exhibit higher CAGR during the forecast period.
Request
Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/5791
Market
Players
Market Research Future (MRFR)
recognizes Johnson & Johnson Services Inc (US), GlaxoSmithKline PLC (UK),
Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG
(Switzerland), Pfizer Inc. (US), Merck & Co. Inc. (US), Sanofi S.A.
(France), Celgene Corporation (US) and Bristol-Myers Squibb Company (US) as the
key players in the global chemotherapy market.
Regional
Analysis
Geographically, the global
chemotherapy market has been segmented into the Americas, Europe, Asia-Pacific,
and Middle East & Africa. As per MRFR analysis, the Americas was the
largest market for chemotherapy in 2018 and is expected to remain dominant
during the review period. Europe accounted for a significant market share and
is projected to be the second-largest market during the forecast period. The
increasing prevalence of cancer is a major driving factor for the growth of the
chemotherapy market in Europe. Germany accounted for the largest market share
of 27.07% in 2018 and projected to register a CAGR of 11.45% during the
forecast period.
Key
Findings of the Study:
The Global Chemotherapy Market
is projected to reach over USD 56,491.59 million by 2024 at an 50% CAGR during
the review period of 2019 to 2024.
Americas accounted for the
largest market share with the US being the major contributor to the growth of
the market.
The breast cancer indication
segment is projected to register the highest CAGR of 11.94% during the forecast
period.
Key manufacturers are adopting
geographic expansions, corporate acquisitions, and product launches as growth
strategies.
Browse Detailed TOC with COVID-19
Impact Analysis at:
https://www.marketresearchfuture.com/reports/chemotherapy-market-5791
About
Market Research Future:
At
Market Research Future (MRFR), we enable our customers to unravel the
complexity of various industries through our Cooked Research Report (CRR),
Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have
supreme objective to provide the optimum quality market research and intelligence
services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email:
sales@marketresearchfuture.com
Comments
Post a Comment